Nivolumab in Patients with Relapsed or Refractory Lymphoid Cancers


Nivolumab in Patients with Relapsed or Refractory Lymphoid Cancers
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Stephen M Ansell, MD, PhD (1/20/15)
Lesokhin AM et al. Preliminary results of a Phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Proc ASH 2014;Abstract 291.

Dr Ansell is Professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota.